stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) EPS (diluted)
TG Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was $2.77, up 1,746.7% from $0.15 in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.74. Over the past ten years it has ranged from −$2.63 (fiscal 2021) to $2.77 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. TG Therapeutics, Inc. ranks 23rd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.77 | 1,746.67% |
| FY2024 | $0.15 | 66.67% |
| FY2023 | $0.09 | — |
| FY2022 | −$1.65 | — |
| FY2021 | −$2.63 | — |
| FY2020 | −$2.42 | — |
| FY2019 | −$1.96 | — |
| FY2018 | −$2.30 | — |
| FY2017 | −$1.91 | — |
| FY2016 | −$1.60 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.05 | (58.33%) |
| Mar 2026 | $0.12 | (14.29%) |
| Dec 2025 | $0.14 | (94.24%) |
| Sep 2025 | $2.43 | 1,329.41% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| TGTX TG Therapeutics, Inc. | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TGTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement